Evidence map›Paper›PMID 33594256›Full record

ArticleExperimental & molecular medicine2021

Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells.

Changyoun Kim, Somin Kwon, Michiyo Iba, Brian Spencer, Edward Rockenstein, Michael Mante, Anthony Adame, Soo Jean Shin, Jerel A Fields, Robert A Rissman and 2 more

RetractedAbstract readRetracted Publication
In one paragraph

Article in Experimental & molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Changyoun KimMolecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. changyoun.kim@nih.gov.ORCID http://orcid.org/0000-0001-9936-8195
Somin KwonMolecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA.
Michiyo IbaMolecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA.
Brian SpencerDepartment of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.
Edward RockensteinDepartment of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.
Michael ManteDepartment of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.
Anthony AdameDepartment of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.
Soo Jean ShinDepartment of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.
Jerel A FieldsDepartment of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.
Robert A RissmanDepartment of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.
Seung-Jae LeeDepartment of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.
Eliezer MasliahMolecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. eliezer.masliah@nih.gov.

Funding

B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging populationZIAAG000936 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2017 to 2025
$4.1M
Neuronal exosomes to identify biomarkers and pathology of deployment-related TBII01BX004312 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI RISBROUGH, VICTORIA B, RISSMAN, ROBERT · 2019 to 2022
–
BLRD VA I01 BX004312NIA NIH HHS R01 AG018440
6 · The paper itself

Abstract

Synucleinopathies are age-related neurological disorders characterized by the progressive deposition of α-synuclein (α-syn) aggregates and include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Although cell-to-cell α-syn transmission is thought to play a key role in the spread of α-syn pathology, the detailed mechanism is still unknown. Neuroinflammation is another key pathological feature of synucleinopathies. Previous studies have identified several immune receptors that mediate neuroinflammation in synucleinopathies, such as Toll-like receptor 2 (TLR2). However, the species of α-syn aggregates varies from study to study, and how different α-syn aggregate species interact with innate immune receptors has yet to be addressed. Therefore, we investigated whether innate immune receptors can facilitate the uptake of different species of α-syn aggregates. Here, we examined whether stimulation of TLRs could modulate the cellular uptake and degradation of α-syn fibrils despite a lack of direct interaction. We observed that stimulation of TLR2 in vitro accelerated α-syn fibril uptake in neurons and glia while delaying the degradation of α-syn in neurons and astrocytes. Internalized α-syn was rapidly degraded in microglia regardless of whether TLR2 was stimulated. However, cellular α-syn uptake and degradation kinetics were not altered by TLR4 stimulation. In addition, upregulation of TLR2 expression in a synucleinopathy mouse model increased the density of Lewy-body-like inclusions and induced morphological changes in microglia. Together, these results suggest that cell type-specific modulation of TLR2 may be a multifaceted and promising therapeutic strategy for synucleinopathies; inhibition of neuronal and astroglial TLR2 decreases pathogenic α-syn transmission, but activation of microglial TLR2 enhances microglial extracellular α-syn clearance.

Indexed as

Immunity, Innatealpha-SynucleinAnimalsAstrocytesBrainCell LineExtracellular SpaceHumansImmunohistochemistryMiceMice, TransgenicMicrogliaModels, AnimalModels, BiologicalNeuronsProtease Inhibitorsalpha-SynucleinProtease InhibitorsReceptors, ImmunologicTLR2 protein, humanToll-Like Receptor 2

Identifiers

PMID33594256
PMCPMC8080790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.